ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association

Journal of the American College of Cardiology

Volumn 53, Issue 17, 2009, Pages 1573-1619

  McLaughlin, Vallerie V ^a   Archer, Stephen L ^a   Badesch, David B ^a   Barst, Robyn J ^a   Farber, Harrison W ^a   Lindner, Jonathan R ^a   Mathier, Michael A ^a   McGoon, Michael D ^a   Park, Myung H ^a   Rosenson, Robert S ^a   Rubin, Lewis J ^a   Tapson, Victor F ^a   Varga, John ^a  

^a NONE

Author keywords

ACCF AHA Expert Consensus Document; endothelin receptor antagonists; hemodynamics; phosphodiesterase inhibitors; prostacyclin; pulmonary arterial hypertension; pulmonary hypertension

Indexed keywords

AMBRISENTAN; AMLODIPINE; BOSENTAN; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VERAPAMIL; WARFARIN;

CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECHOCARDIOGRAPHY; ENDARTERECTOMY; EPISTAXIS; EXERCISE ELECTROCARDIOGRAPHY; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEG EDEMA; LUNG TRANSPLANTATION; MUSCULOSKELETAL PAIN; NAUSEA; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RASH; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

ALGORITHMS; AMERICAN HEART ASSOCIATION; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN; SOCIETIES, MEDICAL; UNITED STATES;

EID: 64849109410     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.01.004     Document Type: Review

References (242)

1. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173 (2006) 1023-1030
2. Thenappan T., Shah S.J., Rich S., et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30 (2007) 1103-1110
3. McGoon M., Gutterman D., Steen V., et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 14S-34S
4. Friedman W.F. Proceedings of National Heart, Lung, and Blood Institute pediatric cardiology workshop: pulmonary hypertension. Pediatr Res 20 (1986) 811-824
5. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114 (2006) 1883-1891
6. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
7. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
8. Archer S., and Rich S. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 102 (2000) 2781-2791
9. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
10. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
11. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
12. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26 (2000) 81-84
13. Trembath R.C., Thomson J.R., Machado R.D., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345 (2001) 325-334
14. Guignabert C., Izikki M., Tu L.I., et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98 (2006) 1323-1330
15. West J., Fagan K., Steudel W., et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94 (2004) 1109-1114
16. Herve P., Launay J.M., Scrobohaci M.L., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99 (1995) 249-254
17. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
18. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
19. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
20. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
21. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569
22. Steudel W., Ichinose F., Huang P.L., et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 81 (1997) 34-41
23. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
24. Marcos E., Adnot S., Pham M.H., et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168 (2003) 487-493
25. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
26. Eddahibi S., Morrell N., d'Ortho M.P., et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J 20 (2002) 1559-1572
27. Bonnet S., Michelakis E.D., Porter C.J., et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113 (2006) 2630-2641
28. Yuan X.J., Wang J., Juhaszova M., et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351 (1998) 726-727
29. Bonnet S., Rochefort G., Sutendra G., et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 104 (2007) 11418-11423
30. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 13S-24S
31. Cowan K.N., Jones P.L., and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105 (2000) 21-34
32. Yuan J.X., and Rubin L.J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 111 (2005) 534-538
33. Simonneau G., Galie N., Rubin L., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl 1 (2004) S5-S12
34. Yigla M., Kramer M.R., Bendayan D., et al. Unexplained severe pulmonary hypertension in the elderly: report on 14 patients. Isr Med Assoc J 6 (2004) 78-81
35. Cogan J.D., Vnencak-Jones C.L., Phillips III J.A., et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 7 (2005) 169-174
36. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68 (2001) 92-102
37. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37 (2000) 741-745
38. Humbert M., Labrune P., Sitbon O., et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur Respir J 20 (2002) 59-65
39. Koehler R., Grunig E., Pauciulo M.W., et al. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. J Med Genet 41 (2004) e127
40. Loyd J.E., Butler M.G., Foroud T.M., et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152 (1995) 93-97
41. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177 (2008) 1377-1383
42. Hachulla E., Gressin V., Guillevin L., et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52 (2005) 3792-3800
43. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62 (2003) 1088-1093
44. Opravil M., Pechere M., Speich R., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155 (1997) 990-995
45. Sitbon O., Lascoux-Combe C., Delfraissy J.F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177 (2008) 108-113
46. Speich R., Jenni R., Opravil M., et al. Primary pulmonary hypertension in HIV infection. Chest 100 (1991) 1268-1271
47. Mehta N.J., Khan I.A., Mehta R.N., et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 118 (2000) 1133-1141
48. McDonnell P.J., Toye P.A., and Hutchins G.M. Primary pulmonary hypertension and cirrhosis: are they related?. Am Rev Respir Dis 127 (1983) 437-441
49. Castro M., Krowka M.J., Schroeder D.R., et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 71 (1996) 543-551
50. Gurtner H.P. Aminorex and pulmonary hypertension. A review. Cor Vasa 27 (1985) 160-171
51. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335 (1996) 609-616
52. Gomez-Sanchez M.A., Saenz de la Calzada C., Gomez-Pajuelo C., et al. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol 18 (1991) 1539-1545
53. Sack K.E., and Criswell L.A. Eosinophilia-myalgia syndrome: the aftermath. South Med J 85 (1992) 878-882
54. Albertson T.E., Walby W.F., and Derlet R.W. Stimulant-induced pulmonary toxicity. Chest 108 (1995) 1140-1149
55. Chin K.M., Channick R.N., and Rubin L.J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. Chest 130 (2006) 1657-1663
56. Castro O., Hoque M., and Brown B.D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 101 (2003) 1257-1261
57. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004) 886-895
58. Anthi A., Machado R.F., Jison M.L., et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 175 (2007) 1272-1279
59. Klings E.S., and Farber H.W. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res 2 (2001) 280-285
60. Rybicki A.C., and Benjamin L.J. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 92 (1998) 2594-2596
61. Aessopos A., Farmakis D., Karagiorga M., et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97 (2001) 3411-3416
62. Hayag-Barin J.E., Smith R.E., and Tucker Jr. F.C. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol 57 (1998) 82-84
63. Abdalla S.A., Gallione C.J., Barst R.J., et al. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 23 (2004) 373-377
64. Dingli D., Utz J.P., Krowka M.J., et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 120 (2001) 801-808
65. Chu J.W., Kao P.N., Faul J.L., et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 122 (2002) 1668-1673
66. Peacock A.J. Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more?. Thorax 60 (2005) 983-984
67. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004) 25S-32S
68. Holcomb Jr. B.W., Loyd J.E., Ely E.W., et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 118 (2000) 1671-1679
69. Okumura H., Nagaya N., Kyotani S., et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 122 (2002) 1096-1098
70. McLaughlin V.V., Presberg K.W., Doyle R.L., et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 78S-92S
71. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
72. Stupi A.M., Steen V.D., Owens G.R., et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29 (1986) 515-524
73. Kuhn K.P., Byrne D.W., Arbogast P.G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
74. Williams M.H., Das C., Handler C.E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 (2006) 926-932
75. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 89 (1994) 2722-2727
76. Hopkins W.E., Ochoa L.L., Richardson G.W., et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15 (1996) 100-105
77. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
78. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
79. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
80. Rosenzweig E.B., Kerstein D., and Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99 (1999) 1858-1865
81. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
82. Barst R.J., Galie N., Naeije R., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28 (2006) 1195-1203
83. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
84. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
85. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
86. Frank H., Mlczoch J., Huber K., et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112 (1997) 714-721
87. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
88. Wensel R., Opitz C.F., Anker S.D., et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106 (2002) 319-324
89. Gomberg-Maitland M., Huo D., Benza R.L., et al. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 26 (2007) 732-738
90. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89 (1994) 1733-1744
91. Eysmann S.B., Palevsky H.I., Reichek N., et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 80 (1989) 353-360
92. Tei C., Dujardin K.S., Hodge D.O., et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 9 (1996) 838-847
93. Yeo T.C., Dujardin K.S., Tei C., et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81 (1998) 1157-1161
94. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 28 (2007) 1250-1257
95. Gan C.T., Lankhaar J.W., Westerhof N., et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 132 (2007) 1906-1912
96. Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006) 1313-1321
97. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
98. Nagaya N., Uematsu M., Satoh T., et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 487-492
99. Torbicki A., Kurzyna M., Kuca P., et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108 (2003) 844-848
100. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
101. McGoon M., Fuster V., Freeman W., Edwards W., and Scott J. Pulmonary hypertension. In: Giuliani E., Gersh B., McGoon M., et al. (Eds). Mayo Clinic practice of cardiology (1996), Mosby, St. Louis, MO 1815-1836
102. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 (1985) 750-756
103. Hinderliter A.L., Willis P.W., Long W.A., et al. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol 91 (2003) 1033-1037 A9
104. Lantheus Medical Imaging. Definity prescribing information (2008). http://www.definityimaging.com/prescribing_info.html Accessed February 11, 2009
105. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
106. Hoeper M.M., Mayer E., Simonneau G., et al. Chronic thromboembolic pulmonary hypertension. Circulation 113 (2006) 2011-2020
107. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
108. Rubin L.J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 7S-10S
109. Hoeper M.M., Maier R., Tongers J., et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 535-541
110. Hoeper M.M., Lee S.H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48 (2006) 2546-2552
111. Fruhwald F.M., Kjellstrom B., Perthold W., et al. Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan. J Heart Lung Transplant 24 (2005) 631-634
112. Wonisch M., Fruhwald F.M., Maier R., et al. Continuous haemodynamic monitoring during exercise in patients with pulmonary hypertension. Int J Cardiol 101 (2005) 415-420
113. Karamanoglu M., McGoon M., Frantz R.P., et al. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest 132 (2007) 37-43
114. Morales-Blanhir J., Santos S., de Jover L., et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98 (2004) 225-234
115. Pepke-Zaba J., Higenbottam T.W., Dinh'Xuan A.T., et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338 (1991) 1173-1174
116. Rubin L.J., Groves B.M., Reeves J.T., et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66 (1982) 334-338
117. Schrader B.J., Inbar S., Kaufmann L., et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 19 (1992) 1060-1064
118. Weir E.K., Rubin L.J., Ayres S.M., et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 140 (1989) 1623-1630
119. Badesch D.B., Abman S.H., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
120. Elliott C.G., Glissmeyer E.W., Havlena G.T., et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113 (2006) 2509-2515
121. Simonneau G., Fartoukh M., Sitbon O., et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114 (1998) 195S-199S
122. Klings E.S., Hill N.S., Ieong M.H., et al. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 42 (1999) 2638-2645
123. Bocchi E.A., Bacal F., Auler Junior J.O., et al. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 74 (1994) 70-72
124. Galie N., Seeger W., Naeije R., et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 81S-88S
125. Mereles D., Ehlken N., Kreuscher S., et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114 (2006) 1482-1489
126. Mohr L.C. Hypoxia during air travel in adults with pulmonary disease. Am J Med Sci 335 (2008) 71-79
127. Weiss B.M., Zemp L., Seifert B., et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 31 (1998) 1650-1657
128. Fuster V., Steele P.M., Edwards W.D., et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
129. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114 (1998) 787-792
130. Aguilar R.V., and Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162 (2000) 1846-1850
131. Kuo P.C., Johnson L.B., Plotkin J.S., et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63 (1997) 604-606
132. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 (1999) 740-743
133. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167 (2003) 1433-1439
134. Rich S., and McLaughlin V.V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 34 (1999) 1184-1187
135. Laliberte K., Arneson C., Jeffs R., et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
136. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
137. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129 (2006) 683-688
138. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
139. Centers for Disease Control and Prevention. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 170-172
140. Doran A., Ivy D., Barst R.J., et al. Guidelines for the prevention of central venous catheter-related bloodstream infections with prostanoid therapy for pulmonary arterial hypertension. Adv Pulm Hypertens 7 (2008) 245-248
141. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
142. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342 (2000) 1866-1870
143. Opitz C.F., Wensel R., Winkler J., et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26 (2005) 1895-1902
144. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
145. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
146. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
147. Sitbon O., McLaughlin V.V., Badesch D.B., et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60 (2005) 1025-1030
148. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
149. Jais X., D'Armini A.M., Jansa P., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFit (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52 (2008) 2127-2134
150. Sitbon O., Gressin V., Speich R., et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
151. Galie N., Rubin L., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371 (2008) 2093-2100
152. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
153. Barst R.J., Rich S., Widlitz A., et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with
154. Galie N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535
155. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. (abstr). Circulation 117 (2008) 3010-3019
156. Gilead. Letairis full prescribing information (2008). http://www.letairis.com/full_prescribing_information.html Accessed February 11, 2009
157. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
158. Hoeper M.M., and Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 354 (2006) 1091-1093
159. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
160. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
161. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28 (2006) 691-694
162. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530
163. Macchia A., Marchioli R., Marfisi R., et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153 (2007) 1037-1047
164. Galie N., Manes A., Negro L., et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30 (2009) 394-403
165. Avouac J., Wipff J., Kahan A., et al. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 67 (2008) 808-814
166. Ambrisentan (Letairis) for pulmonary arterial hypertension. Med Lett Drugs Ther 49 (2007) 87-88
167. Doyle R.L., McCrory D., Channick R.N., et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 63S-71S
168. Klepetko W., Mayer E., Sandoval J., et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 73S-80S
169. Olsson J.K., Zamanian R.T., Feinstein J.A., et al. Surgical and interventional therapies for pulmonary arterial hypertension. Semin Respir Crit Care Med 26 (2005) 417-428
170. Reichenberger F., Pepke-Zaba J., McNeil K., et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 58 (2003) 797-800
171. Rothman A., Sklansky M.S., Lucas V.W., et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 84 (1999) 682-686
172. Sandoval J., Gaspar J., Pulido T., et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32 (1998) 297-304
173. O'Loughlin A.J., Keogh A., and Muller D.W. Insertion of a fenestrated Amplatzer atrial septostomy device for severe pulmonary hypertension. Heart Lung Circ 15 (2006) 275-277
174. Moscucci M., Dairywala I.T., Chetcuti S., et al. Balloon atrial septostomy in end-stage pulmonary hypertension guided by a novel intracardiac echocardiographic transducer. Catheter Cardiovasc Interv 52 (2001) 530-534
175. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
176. Deleted in proof.
177. Cottini S.R., Lerch N., de Perrot M., et al. Risk factors for reperfusion injury after lung transplantation. Intensive Care Med 32 (2006) 557-563
178. Choong C.K., Sweet S.C., Guthrie T.J., et al. Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. J Thorac Cardiovasc Surg 129 (2005) 661-669
179. Kindo M., Radovancevic B., Gregoric I.D., et al. Biventricular support with the Jarvik 2000 ventricular assist device in a calf model of pulmonary hypertension. ASAIO J 50 (2004) 444-450
180. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
181. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
182. Sablotzki A., Czeslick E., Gruenig E., et al. First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance. J Thorac Cardiovasc Surg 125 (2003) 960-962
183. Konstam M.A., and DeNofrio D. Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. Circulation 109 (2004) 143-145
184. Sutsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 (1998) 2262-2268
185. Mylona P., and Cleland J.G. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1 (1999) 197-200
186. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. J Card Fail 8 (2002) 124-127
187. Perez-Villa F., Cuppoletti A., Rossel V., et al. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant 20 (2006) 239-244
188. Brauchlin A.E., Soccal P.M., Rochat T., et al. Severe left ventricular dysfunction secondary to primary pulmonary hypertension: bridging therapy with bosentan before lung transplantation. J Heart Lung Transplant 24 (2005) 777-780
189. Alaeddini J., Uber P.A., Park M.H., et al. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94 (2004) 1475-1477
190. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127 (2005) 1647-1653
191. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59-66
192. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
193. Zile M.R., Baicu C.F., and Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004) 1953-1959
194. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
195. Rosenhek R., Rader F., Klaar U., et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 113 (2006) 2238-2244
196. Bonow R.O., Carabello B.A., Kanu C., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48 (2006) e1-e149
197. Han M.K., McLaughlin V.V., Criner G.J., et al. Pulmonary diseases and the heart. Circulation 116 (2007) 2992-3005
198. Higenbottam T. Pulmonary hypertension and chronic obstructive pulmonary disease: a case for treatment. Proc Am Thorac Soc 2 (2005) 12-19
199. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 20-22
200. Scharf S.M., Iqbal M., Keller C., et al. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166 (2002) 314-322
201. Chaouat A., Bugnet A.S., Kadaoui N., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172 (2005) 189-194
202. Thabut G., Dauriat G., Stern J.B., et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127 (2005) 1531-1536
203. Eddahibi S., Chaouat A., Morrell N., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108 (2003) 1839-1844
204. Alp S., Skrygan M., Schmidt W.E., et al. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 19 (2006) 386-390
205. Madden B.P., Allenby M., Loke T.K., et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 44 (2006) 372-376
206. Maloney J.P. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 9 (2003) 139-143
207. Ryu J.H., Krowka M.J., Pellikka P.A., et al. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82 (2007) 342-350
208. Nathan S.D., Shlobin O.A., Ahmad S., et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 131 (2007) 657-663
209. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 (2003) 735-740
210. Leuchte H.H., Neurohr C., Baumgartner R., et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170 (2004) 360-365
211. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 25 (2005) 783-788
212. Fisher K.A., Serlin D.M., Wilson K.C., et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130 (2006) 1481-1488
213. Atwood Jr. C.W., McCrory D., Garcia J.G., et al. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 72S-77S
214. Moser K.M., and Bloor C.M. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103 (1993) 685-692
215. Bonderman D., Jakowitsch J., Adlbrecht C., et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93 (2005) 512-516
216. Jamieson S.W., Kapelanski D.P., Sakakibara N., et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 76 (2003) 1457-1462
217. Kim N.H. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 (2006) 584-588
218. Feinstein J.A., Goldhaber S.Z., Lock J.E., et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation 103 (2001) 10-13
219. Bresser P., Pepke-Zaba J., Jais X., et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 3 (2006) 594-600
220. Kerr K.M., and Rubin L.J. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest 123 (2003) 319-320
221. Malouf J.F., Enriquez-Sarano M., Pellikka P.A., et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 40 (2002) 789-795
222. Vincens J.J., Temizer D., Post J.R., et al. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. Circulation 92 (1995) II137-II142
223. Yang H., Davidson Jr. W.R., Chambers C.E., et al. Preoperative pulmonary hypertension is associated with postoperative left ventricular dysfunction in chronic organic mitral regurgitation: an echocardiographic and hemodynamic study. J Am Soc Echocardiogr 19 (2006) 1051-1055
224. Costard-Jackle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
225. Aris A., and Camara M.L. As originally published in 1988: long-term results of mitral valve surgery in patients with severe pulmonary hypertension. Updated in 1996. Ann Thorac Surg 61 (1996) 1583-1584
226. Umesan C.V., Kapoor A., Sinha N., et al. Effect of Inoue balloon mitral valvotomy on severe pulmonary arterial hypertension in 315 patients with rheumatic mitral stenosis: immediate and long-term results. J Heart Valve Dis 9 (2000) 609-615
227. Argenziano M., Choudhri A.F., Moazami N., et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 65 (1998) 340-345
228. Chang P.P., Longenecker J.C., Wang N.Y., et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 24 (2005) 998-1007
229. Beck J.R., Mongero L.B., Kroslowitz R.M., et al. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Perfusion 14 (1999) 37-42
230. Santini F., Casali G., Franchi G., et al. Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. Int J Cardiol 103 (2005) 156-163
231. Rea R.S., Ansani N.T., and Seybert A.L. Role of inhaled nitric oxide in adult heart or lung transplant recipients. Ann Pharmacother 39 (2005) 913-917
232. Lowson S.M., Doctor A., Walsh B.K., et al. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med 30 (2002) 2762-2764
233. Fattouch K., Sbraga F., Bianco G., et al. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 20 (2005) 171-176
234. Theodoraki K., Tsiapras D., Tsourelis L., et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 50 (2006) 1213-1217
235. Madden B.P., Sheth A., Ho T.B., et al. Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. Br J Anaesth 93 (2004) 155-156
236. Trachte A.L., Lobato E.B., Urdaneta F., et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 79 (2005) 194-197
237. Carteaux J.P., Roux S., Siaghy M., et al. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Eur J Cardiothorac Surg 15 (1999) 346-352
238. Friedman W.F. Proceedings of National Heart, Lung, and Blood Institute pediatric cardiology workshop: pulmonary hypertension. Pediatr Res 20 (1986) 811-824
239. Roberts K.E., McElroy J.J., Wong W.P., et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24 (2004) 371-374
240. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
241. Yung D., Widlitz A.C., Rosenzweig E.B., et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110 (2004) 660-665
242. Rosenzweig E.B., Ivy D.D., Widlitz A., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 697-704